MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NYSE |
Shares |
342 M |
Market Cap[1] |
$ 1.69 B |
EBITDA (LTM) |
$ -211 M |
P/E (LTM) |
-11.35 |
P/S (LTM) |
36.976475 |
EPS (LTM) |
-0.6 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Ionis Pharmaceuticals
IONS
|
$ 43.5 | 0.62 % | $ 6.96 B | Nasdaq Global Select Market,SPB | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.25 | 0.88 % | $ 1.81 B | Nasdaq Global Select Market,SPB | USA |
|
Foghorn Therapeutics
FHTX
|
$ 2.0 | 0.74 % | $ 126 M | Nasdaq Global Market | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 2.0 | 0.5 % | $ 197 M | Nasdaq Capital Market | USA |
 |
Kamada Ltd.
KMDA
|
$ 8.0 | 1.34 % | $ 461 M | Nasdaq Global Select Market |  Israel |
 |
Intellia Therapeutics
NTLA
|
$ 12.75 | 4.0 % | $ 1.38 B | Nasdaq Global Market,SPB | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.5 | 3.19 % | $ 1.43 B | Nasdaq Global Select Market,SPB | USA |
 |
Viridian Therapeutics
VRDN
|
$ 19.0 | 2.16 % | $ 1.93 B | Nasdaq Capital Market | USA |
 |
AbbVie
ABBV
|
$ 265.76 | 1.12 % | $ 470 B | NYSE,SPB | USA |
 |
AbCellera Biologics
ABCL
|
$ 13.78 | 0.29 % | $ 4.12 B | Nasdaq Global Select Market |  Canada |
 |
Abeona Therapeutics
ABEO
|
$ 5.11 | 1.59 % | $ 271 M | Nasdaq Capital Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.67 | 4.94 % | $ 895 M | Nasdaq Global Select Market | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 20.11 | 0.8 % | $ 3.39 B | Nasdaq Global Select Market,SPB | USA |
 |
Achieve Life Sciences
ACHV
|
$ 7.01 | 0.13 % | $ 306 M | Nasdaq Capital Market | USA |
 |
AC Immune SA
ACIU
|
$ 2.71 | 0.55 % | $ 273 M | Nasdaq Global Market |  Schweiz |
 |
Aclaris Therapeutics
ACRS
|
$ 4.27 | 0.79 % | $ 523 M | Nasdaq Global Select Market | USA |
 |
Adagene
ADAG
|
$ 2.8 | 0.28 % | $ 165 M | Nasdaq Global Market |  China |
 |
ADC Therapeutics SA
ADCT
|
$ 1.23 | 8.85 % | $ 156 M | NYSE | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
$ 4.35 | 5.58 % | $ 2.91 M | Nasdaq Capital Market | USA |
 |
ADMA Biologics
ADMA
|
$ 10.11 | 4.01 % | $ 2.41 B | Nasdaq Global Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 29.84 | 5.26 % | $ 4.53 B | Nasdaq Global Select Market,SPB | USA |
 |
Agenus
AGEN
|
$ 8.73 | 4.43 % | $ 260 M | Nasdaq Capital Market | USA |
 |
AIM ImmunoTech
AIM
|
$ 0.19 | 5.56 % | $ 308 K | NYSE American | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.91 | 5.26 % | $ 234 M | Nasdaq Global Market | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.76 | 0.46 % | $ 590 B | Nasdaq Capital Market |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.92 | 4.88 % | $ 55.3 M | Nasdaq Global Select Market | USA |
 |
Alector
ALEC
|
$ 1.99 | 9.94 % | $ 205 M | Nasdaq Global Select Market,SPB | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.4 | 0.36 % | $ 53.4 M | Nasdaq Global Select Market | USA |
 |
Alkermes plc
ALKS
|
$ 42.76 | 2.42 % | $ 7.04 B | Nasdaq Global Select Market |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.5 | 0.33 % | $ 331 M | Nasdaq Global Select Market,SPB | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 219.89 | 0.08 % | $ 28.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Altimmune
ALT
|
$ 2.67 | 0.36 % | $ 235 M | Nasdaq Global Market | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.21 | 1.23 % | $ 64.9 M | Nasdaq Global Select Market,SPB | USA |
 |
Amgen
AMGN
|
$ 402.98 | 0.08 % | $ 217 B | Nasdaq Global Select Market,SPB | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.37 | 0.39 % | $ 1.19 B | Nasdaq Global Select Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 12.09 | 0.31 % | $ 5.02 B | Nasdaq Global Market | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 20.35 | 0.25 % | $ 6.38 B | NYSE | USA |
 |
AnaptysBio
ANAB
|
$ 49.2 | 1.38 % | $ 1.43 B | Nasdaq Global Select Market,SPB | USA |
 |
Anika Therapeutics
ANIK
|
$ 19.73 | 3.3 % | $ 283 M | Nasdaq Global Select Market,SPB | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.58 | 0.55 % | $ 1.46 B | Nasdaq Global Market,SPB | USA |
 |
Annexon
ANNX
|
$ 4.2 | 0.24 % | $ 651 M | Nasdaq Global Select Market | USA |
 |
Annovis Bio
ANVS
|
$ 1.2 | 1.69 % | $ 24.7 M | NYSE American | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.68 | 0.16 % | $ 4.45 M | Nasdaq Global Select Market,SPB | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.8 | 2.27 % | $ 568 K | Nasdaq Capital Market | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.57 | 0.44 % | $ 489 M | Nasdaq Global Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 14.66 | 12.51 % | $ 401 M | Nasdaq Global Market,SPB | Israel |
 |
Ardelyx
ARDX
|
$ 3.39 | 1.5 % | $ 817 M | Nasdaq Global Market | USA |
 |
argenx SE
ARGX
|
$ 912.87 | 1.28 % | $ 56 B | Nasdaq Global Select Market |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.66 | 3.98 % | $ 133 M | NYSE American | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 25.15 | 0.04 % | $ 3.2 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.